Debt-laden Glenmark counts on assets sales, spinoffs to dig it out
admin 16th August 2019 Uncategorised 0Glenmark Pharmaceuticals’ makeover is painfully loaded with slow revenue growth and high capital spend simultaneously. In the hope of reducing debt, the Indian drugmaker now plans to sell some of its noncore assets after spinning off its API and innovative R&D businesses.
More: Debt-laden Glenmark counts on assets sales, spinoffs to dig it out
Source: fierce